Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the efficacy of Avastin in combination
with temozolomide and irinotecan in terms of response rate. The secondary objectives are to
describe the overall and progression-free survivals of unresectable patients treated with
upfront Avastin, temozolomide and irinotecan and to assess the safety of Avastin,
temozolomide and irinotecan in unresectable glioblastoma patients.
This is a phase II study with the combination of Avastin, temozolomide and irinotecan for
unresectable or multifocal World Health Organization (WHO) grade IV malignant glioma
patients. Patients will receive up to four cycles of Avastin, temozolomide and irinotecan.
Approximately 41 subjects will take part in this study at Duke.